NCT00747123 · REGISTRY CONDITION SEARCH

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2024-10-03

Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

→

outcome · POSTED

Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

→

outcome · POSTED

Number of Participants With Serious Adverse Events (SAEs)

→

outcome · POSTED

Change From Baseline in Hemoglobin

→

outcome · POSTED

Number of Participants With Electrocardiogram Abnormalities

→

outcome · POSTED

Number of Participants With Hypertension or Increased Blood Pressure

→

outcome · POSTED

Number of Participants With Skeletal-related Events (SRE)

→

outcome · POSTED

Percent Change From Baseline in Bone Pain Visual Analog Scale (VAS)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Key Inclusion Criteria: * Patient at least 18 years of age with stage II or III multiple myeloma * One or more lytic bone lesions * If currently receiving bisphosphonate therapy, have been on a stable dose for ≥ 2 months before dosing day 1 or must not have received bisphosphonates within 2 months of dosing day 1 * If patient has undergone previous autologous or allogenic hematopoietic stem cell transplantation (HSCT), they must be stable (in the opinion of the investigator) and be a minimum of 6 months since HSCT * Has planned HSCT for the duration of the study * Has moles or lesions that are currently undiagnosed, but are suspect for malignancy * Has an underlying condition that may result in abnormal bone metabolism other than cancer related bone lesions, such as a history of hyperparathyroidism, hypoparathyroidism, hypocalcemia, rheumatoid arthritis, myeloproliferative disorder, gout, Paget's disease of the bone, or osteomalacia; patients with a diagnosis of osteoporosis prior to multiple myeloma diagnosis are eligible to participate. Key Exclusion Criteria: * Known underlying condition that may result in abnormal bone metabolism other than cancer related bone lesions * History of polyneuropathy ≥ grade 3 * Patients with plasma cell leukemia * Planned stem cell transplant (HSCT) or radiation for the duration of the study * Skeletal related event within 2 weeks of study enrollment * Has received erythropoiesis-stimulating agents (ESAs) within the last 21 days or is planned to receive ESAs during the course of the study * Has received anti-myeloma therapy within the last 21 days * Is scheduled to receive local radiation to bone during the course of the study * Has taken estrogen, androgen, anabolic steroids, calcitonin or other bone-active drugs within 4 months of study enrollment * Woman of childbearing potential (not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months)
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Subcutaneous injection on days 1, 29, 57 and 85.
intervention Names
Biological: Placebo
label
Placebo
type
PLACEBO_COMPARATOR
description
Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
intervention Names
Biological: ACE-011
label
ACE-011 0.1 mg/kg
type
EXPERIMENTAL
description
Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
intervention Names
Biological: ACE-011
label
ACE-011 0.3 mg/kg
type
EXPERIMENTAL
description
Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
intervention Names
Biological: ACE-011
label
ACE-011 0.5 mg/kg
type
EXPERIMENTAL

interventions

arm Group Labels
ACE-011 0.1 mg/kg
ACE-011 0.3 mg/kg
ACE-011 0.5 mg/kg
description
ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
name
ACE-011
other Names
hActRIIA-IgG1
type
BIOLOGICAL
arm Group Labels
Placebo
description
Placebo given by the subcutaneous route of administration monthly for 4 doses.
name
Placebo
type
BIOLOGICAL

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: DOUBLE
who Masked: PARTICIPANT
INVESTIGATOR

primary Purpose

TREATMENT

Enrollment

count: 30
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
A treatment emergent adverse event (TEAE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causality assessment. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported.
measure
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
time Frame
From first dose to termination visit on Day 169
description
A treatment emergent adverse event (TEAE) related to study drug was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, that was determined to be related to the study drug. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported. Treatment emergent adverse events were assessed by the investigator as possibly, probably, or definitely related to the study drug.
measure
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
time Frame
From first dose to termination visit on Day 169
description
A Serious Adverse Event (SAE) was defined as any untoward medical occurrence that at any dose (including overdose) that was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in permanent or significant disability/incapacity, or was a congenital anomaly/birth defect. The number of participants with at least one serious adverse event are reported.
measure
Number of Participants With Serious Adverse Events (SAEs)
time Frame
From first dose up to termination visit on Day 169
description
Summary of the change from baseline in hemoglobin (g/dL) by the pre-specified timepoints. Baseline was defined as the last measurement prior to dosing. Data were summarized for all treated participants who had at least 1 postdosing measurement.
measure
Change From Baseline in Hemoglobin
time Frame
Day 1 (baseline), Day 8, Day 29, Day 36, Day 57, Day 85, Day 113, Day 169
description
The number of participants with at least one clinically significant postbaseline electrocardiogram abnormality. The abnormalities included left ventricular hypertrophy, atrial fibrillation, sinus bradycardia, sinus tachycardia, and myocardial ischemia. Data is reported as the cumulative number of participants with abnormalities over the scheduled collection timepoints.
measure
Number of Participants With Electrocardiogram Abnormalities
time Frame
Pre-dose, Day 1, Day 92, and Day 169
description
The number of participants who experienced hypertension or an increase in blood pressure from baseline up to Day 92. Abnormal blood pressure was defined as: * Systolic blood pressure ≤ 90 or ≥ 180 mmHg * Systolic blood pressure change (increase or decrease) ≥ 20 mmHg * Diastolic blood pressure ≤ 60 or ≥ 100 mmHg * Diastolic blood pressure change (increase or decrease) ≥ 15 mmHg
measure
Number of Participants With Hypertension or Increased Blood Pressure
time Frame
From baseline up to Day 92

secondary Outcomes

description
Skeletal-related events are defined as pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression, within 2 weeks of study enrollment. They are determined by skeletal surveys, including x-rays of the skull, entire spine, pelvis, ribs, humeri, and femora.
measure
Number of Participants With Skeletal-related Events (SRE)
time Frame
From first dose up to 2 weeks post first dose
description
The visual analog scale (VAS) is a pain rating scale. Scores are based on the percent change from baseline (Day 1) in self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm). Measurements from the starting point (left end) of the scale to the patients' marks are recorded in centimeters and are interpreted as their pain. The values can be used to track pain progression for a patient or to compare pain between patients with similar conditions. In addition to pain, the scale has also been used to evaluate mood, appetite, asthma, dyspepsia, and ambulation.
measure
Percent Change From Baseline in Bone Pain Visual Analog Scale (VAS)
time Frame
From baseline (Day 1) to Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

Full study description

brief Summary: Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.

Source references

references

citation
Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21.
pmid
24650009
type
BACKGROUND

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8ec0fd9d9051398b526d
requested nct id
NCT00747123
primary nct id
NCT00747123
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
77b1eb0b15aa3742fde851ca83498c8044cd863da83d3dfe6aa64a3327a46487
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8ec0fd9d9051398b526d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00747123
occurrences
context exact
NCT00747123
end
11
exact text
NCT00747123
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/649/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
177eab6ef80d1cda35972bc8c302e290e35ebb507862122bd798594d0abfce4b
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice